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g.2014.0Abstract Background: Lipodermatosclerosis (LDS) is considered a type of panniculitis (inﬂam-
mation of subcutaneous fat). Patient experiences severe pain, increased stress, swelling, walking
problems and decreased quality of life. The end result of untreated LDS is ulcer formation with high
incidence of delayed healing and infection. In addition to psychological problem, the ﬁnancial costs
can be signiﬁcant.
Aim of the study: To evaluate the efﬁcacy of ultrasonic waves (U.S.) in the treatment of
lipodermatosclerosis.
Methods: Forty patients with lipodermatosclerosis from both sexes aged from 42 to 65 years
were assigned into two groups of equal number. The study group (group A) received continuous
U.S. three times/week at frequency of 3 MHz in addition to routine treatment which consisted of
wearing grade 2 compression stocking (30–40 mmHg) during weight bearing conditions, patients
were advised to try to decrease weight bearing as much as possible during the treatment period
and circulatory exercise for 15 min at least 5 times/day, control group (group B) received placebo
U.S. plus routine treatment. Pain sensation and skin hardness were assessed in both groups using
numeric rating scale (NRS) and durometer.
Results: The results revealed a signiﬁcant decrease in mean values of pain sensation and skin
hardness in the study group compared to the control group after treatment.
To conclude that therapeutic ultrasound was effective in controlling of lipodermatosclerosis dis-
ease as regards, decreasing pain sensation and skin hardness.
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Lipodermatosclerosis (LDS) is characterized by lower leg
inﬂammation and woody induration in patients with chronic
venous or lymphatic hypertension [1]. Lipodermatosclerosis
takes grade 4 on CEAP scale which is a graded scale that
includes six grades and classiﬁes venous diseases according
to its severity based on clinical, etiologic, anatomic and
pathologic aspects [2,3]. Lipodermatosclerosis may present asin Shams University.
194 S.A. Hamid et al.an acute or as a chronic (longstanding) condition. Chronic
lipodermatosclerosis (CLDS) may follow an acute episodes
or develop gradually [4].
Acute lipodermatosclerosis (ALDS) presents as episodes of
painful inﬂammation in the inner leg above the ankle, resem-
bling cellulitis [5]. The affected area is painful and inﬂamed,
red or purple in color with poorly demarcated plaques, often
with indurated and edematous skin of the medial calf. Some
thickening of the skin can be felt. Patients with acute lipoder-
matosclerosis are mainly middle-aged [4]. Histologically,
ALDS is mostly a lobular panniculitis with increased fat
sclerosis, membranous necrosis and microcysts [6].
Common ﬁndings in chronic lipodermatosclerosis (CLDS)
include pain, hardening of the skin, localized thickening, mod-
erate redness, increased pigmentation, small white scarred
areas (atrophie blanche), increased ﬂuid in the leg (edema),
varicose veins and leg ulcers. Chronic lipodermatosclerosis
also predisposes to venous or stasis eczema [4].
Unless the underlying cause of the LDS is treated, the pa-
tient is at a high risk of developing a painful and potentially
chronic venous leg ulcer [7]. Patients experience increased
stress, pain, decreased quality of life and difﬁculty in coping
with the symptoms and manifestations of the disease. In
addition to the psychosocial problems, the ﬁnancial costs can
be signiﬁcant [8].
In lipodermatosclerosis, the microvascular network is af-
fected by the consequences of venous hypertension [9]. Several
groups suggest that the subcutaneous vasculature is the ﬁrst to
be affected, leading to ischemic fat necrosis and panniculitis
[10,11]. Whereas others propose that the papillary plexus in
the upper dermis of the skin is initially affected [9,12,13].
The cellular and molecular mechanisms leading to the for-
mation of LDS from venous hypertension are not known; it is
likely to be multifactorial. Raised intravascular pressure, pro-
duced as a consequence of venous hypertension, is known to
affect the capillary network of the skin in a manner as to cause
enhanced ﬁltration of ﬂuid, leakage of plasma proteins such as
ﬁbrinogen and extravasation of erythrocytes [1,9].
Since the ﬁbrinolytic activity of the blood and the tissues is
deﬁcient in patients with venous hypertension, any ﬁbrinogen
which is converted to ﬁbrin in the interstitial spaces is less
likely to be broken down or reabsorbed [14].
A sheet of ﬁbrin appears to allow carbon dioxide to pass
through it relatively freely but this sheet is relatively imperme-
able to the passage of oxygen, which leads to ischemia and
destruction of tissues [15,16]. Moreover, patients with LDS
may produce lower levels of plasminogen activator coupled
with a simultaneous presence of elevated levels of its inhibitors
in blood and tissues [17]. There is clear evidence of leukocytes’
activation in venous disease and many inﬂammatory mecha-
nisms are up-regulated in the skin [18].
2. Ethical consideration
The study protocol was explained in details for each patient
before the initial assessment and signed informed consent
was obtained from each patient before enrollment in the study
(or their families). . .This study was approved by the meeting of
the department of Physical therapy for surgery and the
ethics committee of the Faculty of Physical Therapy, Cairo
University. The study is also carried out in accordance withthe code of Ethics of the World Medical Association
(Declaration of Helsiniki) for experiments involving humans.3. Patients and methods
3.1. Subjects
This controlled randomized study was conducted to determine
the effect of U.S. waves in controlling pain and skin durability
in patients suffering from lipodermatosclerosis. Forty patients
with lipodermatosclerosis had met the inclusion and exclusion
criteria. The age ranged between 42 and 65 years old. They
were divided randomly into two equal groups. Following the
baseline evaluation of each patient, a closed envelope was ran-
domly selected that contained the patient’s group allocation.
Group (A) the study group, received continuous ultrasound
wave (3 MHz – 3 sessions/week), in addition to the routine
treatment which consisted of grade 2 compression stocking
at pressure from 30–40 mmHg. Patients wore compression
stocking mainly during weight bearing conditions. Patients
were advised to try to decrease weight bearing as much as pos-
sible during the treatment period, and to do circulatory exer-
cises for 15 min at least 5 times/day. Group (B) the control
group, received placebo ultrasound wave in addition to the
same routine treatment. Patients were excluded if he/she had
skin malignancy, open wound or ulcer at the site of treatment,
skin infection at the treated area, psychological or mental
problems, occupational and/or above-average recreational
weight bearing requirements, dermatological condition rather
than LDS at the treatment site as well as one of the ultrasound
contraindications. Patients who received previous physical
therapy program for LDS were also excluded from the study.
3.2. Methods of evaluation
Primary medical examination was done to every patient to get
a complete medical picture of the health status of the patient
and to know if the patient was able to undergo the study or
if there were any contraindications.
Measurements were performed under standardized condi-
tions taking into consideration that:
 Measurements were carried out by the same investigator.
 The same area was assessed before and after therapy for
each patient.
 The patients were given 10 min. to adapt to room condi-
tions and this constant for all patients.
 Measurements were always carried out with the patient in a
resting position.
3.2.1. Pain assessment
Patients were asked to determine their degree of pain using the
numeric rating scale (NRS); pre-treatment, after 4 weeks of the
treatment (Post I) and after 8 weeks, at the end of the study
(Post II) to determine the severity of pain. NRS is a scale with
approximately ten severity grades. The NRS is graded from 0
(no pain) to 10 (maximum pain). Grades of NRS were ex-
plained for patients for more accurate expression of their pain
degree.
The response of skin hardness and pain sensation to ultrasonic treatment in lipodermatosclerosis patients 1953.2.2. Skin hardness
Durometer was also used to determine the state of LDS skin.
Durometer (Model Digital DD-3, Type 00, Rex Gauge, IL,
and USA) was used pre-treatment and post-treatment (after
8 weeks) for the measurement of skin hardness. Skin hardness
was conducted on two sites, 5 and 10 cm superior to the medial
malleolus of the ankle. For the measurements, subjects were
laying on their lateral side (side laying position) with the re-
quired leg lying in contact with the examination table in a
semi-ﬂexed position with the ankle supported by a pillow. This
position allowed the durometer to be both perpendicular to the
leg and table top and allowing the use of gravity for skin
indentation without any angulations. These sites were chosen
because of their presence in the affected area, not over bony
prominence and were easily standardized. The durometer usu-
ally was placed perpendicular on the skin without exerting any
pressure in order to avoid any external force using the effect of
gravity.
3.3. Treatment procedure
Patients were asked to stop any drug that had any effect on the
present study before the beginning of the study by at least
2 weeks for a topical one, and by 4 weeks for an oral one.
All patients were instructed to wear grade 2 compression
stockings (30–40 mmHg) [1]. Also patients were asked to fol-
low the dermatologist instructions (as sterilizing the affected
area continuously, prevention of any increase in weight and
prevention of prolonged weight bearing), that was started be-
fore the beginning of the treatment procedure by at least
2 weeks and until the end of the study.
Group (A): study group
Patients received 3 MHz continuous ultrasound (Ultracom-
bi-707 ultrasonic device is a therapeutic U.S. device manufac-
tured by Dae Yang medical CO. Ltd,Korea), 3 sessions/week
for 8 weeks. We began with an intensity of 0.7 W/cm2 for
5 min per 50-cm2 area (in ﬁrst 2 weeks) to capture thermal ef-
fects of U.S., and then increased the intensity to 1 W/cm2 for
8 min per 50 cm2 (for the following 2 weeks) then the intensity
was increased to 1.5 W/cm2 for 10 min per 50 cm2 (in the next
4 weeks) to capture both the thermal and non-thermal effects
of the U.S., in addition to the previously mentioned routine
treatment.
Group (B): control group
Patients received a placebo U.S. therapy plus the previously
mentioned routine treatment.Table 1 Statistical analysis of the demographic and clinical characte
study.
Groups Group (A) (n= 20)
Variables
Age (years) 61.53 ± 12.22
Sex (male/ female) 9/11
BMI 29.36 ± 4.98
X=Mean, SD= Standard deviation, P-value = Probability level, BMI
* Non-signiﬁcant (P> 0.05).4. Statistical analysis
Statistical analysis was performed using The Statistical Pack-
age for Social Science (SPSS). For each variable the mean
and standard deviation were calculated. Paired T test was used
to compare the dependent variable (pain and skin hardness),
within each group to detect the level of signiﬁcance. Unpaired
T-test was applied to compare the dependent variable (pain
and skin hardness), and independent variables (age, sex, and
BMI) between the two groups to detect the level of signiﬁ-
cance. P-values less than 0.05 were considered to be statisti-
cally signiﬁcant, NRS was compared at the start, after four
sessions and at the end of the treatment using ANOVA test
for dependent variables.5. Results
5.1. Demographic and clinical characteristic of the patients
As revealed from (Table 1), There were no statistical signiﬁ-
cant differences between the mean values of the two groups
concerning general characteristics of age, sex and Body mass
index at the beginning of treatment. (P> 0.05). Table 2 repre-
sents the Frequency of some accompanied medical conditions
in both study and control groups.
5.2. Results of NRS (numerical rating scale) for the two groups
(pre, post I and post II) are included in Table 3 and Figs. 1,2
The results of this study revealed that there was no signiﬁcant
difference in pain sensation measured by NRS between control
and study groups at the beginning of the study (P> 0.05).
Comparison between control and study groups post I, and
after 8 weeks (post II) revealed that there was a signiﬁcant de-
crease in pain sensation measured by NRS in the study group
compared to the control group (P values = 0.0001 and 0.0001
respectively). Pain sensation decreased by 53.1% (p va-
lue = 0.0001) after 4 weeks of US treatment, while application
reduction in pain sensation by 87.58% (p value = 0.0001) after
2 months of treatment in the treatment group.
5.3. Results of skin hardness for the two groups (pre and post-
treatment) are included in Table 4 and Fig. 3
It was found that application of U.S. up to 2 months achieved
a statistically signiﬁcant decrease in skin hardness at the level
of 5 cm measurement and 10 cm measurement above the
medial malleolus by 21.56% and 19.4% respectively in theristics of patients between the two groups at the beginning of the
Group (B) (n= 20) P-value
58.8 ± 12.13 0.51*
10/10 0.89*
28.66 ± 4.48 0.64*
= Body Mass Index.
Figure 2 Comparison of NRS (post I and post II) between both
groups (study and control).
Figure 1 Comparison of NRS (pre-treatment) between both
groups (study and control).
Table 2 Frequency of some accompanied medical conditions
in both study and control groups.
Item Study Control
Diabetes 14 (70%) 12 (60%)
Hypertension 14 (70%) 11 (55%)
Smoking 4 (20%) 6 (30%)
Varicose veins 15 (75%) 12 (60%)
Valve incompetence 11 (55%) 11 (55%)
Old thrombosis 7 (35%) 4 (20%)
196 S.A. Hamid et al.treatment group while the control group skin hardness de-
creased by 2.43% and 3.04% respectively (P Value = 0.0001).
Fig. 4(a and b) shows the difference between an
affected area pre and post application of ultrasonic while
Fig. 5(a and b) shows the difference between an affected area
pre and post for the control group.
6. Discussion
Ultrasonic (US) treatment of LDS was reported for the ﬁrst
time more than 30 years ago by Rowe and Cantwell [19].
Our results prove the efﬁcacy of the U.S. treatment in improv-
ing skin tone and pain sensation in patients with lipodermato-
sclerosis. Throughout the study, there was no complain from
any adverse effect of ultrasonic treatment, whereas, ﬁve pa-
tients (12.5%) complained from feeling pain due to wearing
compression stocking but they completed the study.
The therapeutic effects of ultrasonic include reducing
inﬂammation and swelling, increasing soft tissue extensibility,
speeding metabolism, improving blood ﬂow, reducing nerve
root irritation, breaking up scar tissue and adhesions, creating
a deep heat to a localized area much deeper than can be
achieved with a hot pack and facilitating healing at the cellular
level [20–22].
Our results were supported by many previous studies, such
as that of Diona and colleagues [1] who proved that continu-
ous ultrasonic application to LDS patients, signiﬁcantly re-
duced skin hardness by 60%, reduced Erythema by 46% in 7Table 4 Results of skin hardness for the two groups (Pre and Post
Groups Level of
measurement
Mean Standa
Pre Post Pre
Group A (study
group)
At 5 cm 20.4 16 1.75
At 10 cm 21 17 1.29
Group B (control
group)
At 5 cm 20.5 20 1.67
At 10 cm 21.35 20.7 1.03
Table 3 Results of NRS (numerical rating scale) for the two group
Groups Mean Standard deviatio
Pre Post I Post II Pre Post I
Group A 7.25 3.4 0.9 1.25 0.82
Group B 6.8 5.65 3.65 1.43 1.66of the 9 legs with erythema indices and rapidly alleviated
symptoms.
Ultrasonic effect on LDS may be attributed to the immuno-
modulatory and anti-inﬂammatory effects of ultrasound).
rd deviation t-
Value
P-
value
Percent of
improvement (%)
Sig.
Post
1.16 11.18 0.0001 21.56 S
1.16 12.32 0.0001 19.04 S
1.29 1.56 0.13 2.43 NS
1.45 1.68 0.1 3.04 NS
s (Pre, Post I and Post II).
n F-value P-value Percent of improvement
Post II
0.71 375.68 0.0001 87.58
1.42 55.12 0.0001 46.32
Figure 3 Comparison between pre and post treatment mean
values of skin hardness of both groups (study and control).
Figure 4a Shows an affected area pre-application of ultrasonic
for a case with lipodermatosclerosis.
Figure 4b Shows an affected area post-application of ultrasonic
for a case with lipodermatosclerosis.
Figure 5a Shows an affected area pre-application of placebo
ultrasonic for a case with lipodermatosclerosis.
Figure 5b Shows an affected area post-application of placebo
ultrasonic for a case with lipodermatosclerosis.
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teinase and promotion of circulation [23–25].This may also be due to speeding up metabolism and
improving blood ﬂow Promoting angiogenesis, Stimulation
of ﬁbroblast proliferation with ultrasound, and increase in col-
lagen deposition,
It may lead also to reduction of inﬂammation, swelling and
nerve root irritation, increase in soft tissue extensibility, facil-
itating healing at a cellular level and reversal of both the ﬁbro-
tic and inﬂammatory changes of LDS [1,20,26–28].
Also it was found that pulsed ultrasonic can promote circu-
lation. Application of ultrasound on alternate days for a peri-
od of either 1 or 3 weeks improved arterial blood ﬂow which
may improve any condition resulting from poor blood supply
[20,25]. Other effects have also been observed in vivo studies,
such as changes in the plasma membrane and in intracellular
organelles such as lysosomes and mitochondria [27].
However, our results disagreed with Flemming and Cullum
[29], and Baba-Akbari Sari et al. [30],. Flemming and Cullum
[29] suggested that, there might be some improvement in the
healing rate of venous ulcers associated with the use of thera-
peutic ultrasonic, though no trial found a signiﬁcant effect of
ultrasound therapy in the healing of venous leg ulcers. These
results should be taken with caution as there were only seven
198 S.A. Hamid et al.poor quality trials with a total of 274 patients involved,
making it difﬁcult to determine clinically important effects.
7. Conclusion
Within the limitations of the present study, the notable conclu-
sions are:
The ultrasound therapy (U.S.) with previously mentioned
parameters is a useful approach in controlling lipodermato-
sclerosis; in expression of reducing pain, reducing skin
thickness, and improving of the appearance.
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